Investor Presentaiton

From "3 and Alpha" to "5DXd-ADCs and Next Wave" ENHERTU Dato-DXd BADCs 5DXd-ADCS HER3-DXd & DS-7300 (I-DXd) Alpha & Next Wave DS-6000 (R-DXd) Oncology Specialty Medicine & Vaccine Maximize 5DXd-ADCs Values Next Pillars Daiichi-Sankyo ENHERTU®: trastuzumab deruxtecan (International Nonproprietary Name: INN), T-DXd, DS-8201 (HER2-directed ADC), Dato-DXd: datopotamab deruxtecan (INN), DS-1062 (TROP2-directed ADC), HER3-DXd: patritumab deruxtecan (INN), U3-1402 (HER3-directed ADC), DS-7300: ifinatamab deruxtecan, I-DXd (B7-H3-directed ADC), DS-6000: raludotatug deruxtecan, R-DXd (CDH6-directed ADC) 17

View entire presentation